A single protein may be holding back CAR T cancer therapy
Scientists have identified a protein called NFIL3 that contributes to the exhaustion of CAR T cells in cancer therapy. By using CRISPR technology to disable this protein, researchers were able to improve the effectiveness of immune cells against solid tumors.
Why it matters
Overcoming CAR T-cell exhaustion is a major hurdle in cancer treatment, and this finding could significantly improve outcomes for patients with solid tumors.
Researchers from Columbia University and University Hospital T bingen have discovered a protein that appears to play a major role in weakening CAR T cells over time. By disabling the protein, known as NFIL3, the scientists found that these engineered immune cells remained active longer and were better able to attack tumors. The findings, published in Cancer Discovery , could help improve CAR T-cell therapy, particularly against solid tumors that have proven difficult to treat.
The article provides a technical summary of medical research without subjective framing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in